Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

BMC Infect Dis · 2005 · PMC548524 · PMID 15647105

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendP = 0.052so close (0.05 < p ≤ 0.1)

The abacavir-switch arm showed a trend for greater LSM reduction from baseline in free fatty acids (-0.3 vs -0.2 mEq/L; P = 0.052).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.